{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidcp6ke7twxmim4csow2axdqyekldnjb63vahfn2wgbrh7xzbsepu",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3me5ctec4yba2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihf4btslafutg6sygqxjpcsoa4g3q7dqcxquqp2bl57nitsonx7yy"
    },
    "mimeType": "image/jpeg",
    "size": 208090
  },
  "path": "/news/2026-02-medication-chances-clot.html",
  "publishedAt": "2026-02-05T16:00:05.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Diseases, Conditions, Syndromes"
  ],
  "textContent": "An investigational anti-clotting medication, asundexian, has demonstrated a reduction in the risk of a second ischemic (clot-caused) stroke without raising bleeding concerns, according to a preliminary late-breaking science presentation at the American Stroke Association's International Stroke Conference 2026.",
  "title": "New medication may reduce chances of a second clot-caused stroke without bleeding risk"
}